[HTML][HTML] Heparin and derivatives for advanced cell therapies

S Laner-Plamberger, M Oeller, E Rohde… - International Journal of …, 2021 - mdpi.com
… (ARDS) due to the novel corona-virus disease 2019 (COVID-19) in the current pandemic [38]…
of COVID-19 infection, an elevation of the coagulation potential may require higher heparin

[HTML][HTML] Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality

HH Billett, M Reyes-Gil, J Szymanski… - Thrombosis and …, 2020 - thieme-connect.com
… significant for mortality in COVID-19 and that patients with COVID-19 are at increased risk of
… with severe COVID-19 were retrospectively analyzed regarding the potential benefit of AC.[7…

[HTML][HTML] Low molecular weight heparin in COVID-19: benefits and concerns

A Makarem, R Zareef, J Abourjeili, JE Nassar… - Frontiers in …, 2023 - frontiersin.org
… We review its pharmacology, mechanism of action, clinical uses, course of treatment pre,
post, and during hospitalization, and discuss its potential use for disease prophylaxis versus …

Network pharmacology-and molecular simulation-based exploration of therapeutic targets and mechanisms of heparin for the treatment of sepsis/COVID-19

Y Fang, S Lin, Q Dou, J Gui, W Li, H Tan… - Journal of …, 2023 - Taylor & Francis
… therapeutic actions of heparin in sepsis/COVID-19 from the … potential targets for heparin
action against sepsis/COVID-19 … that heparin could help in treating sepsis/COVID-19 through …

[HTML][HTML] Heparin and its derivatives: challenges and advances in therapeutic biomolecules

N Banik, SB Yang, TB Kang, JH Lim, J Park - International journal of …, 2021 - mdpi.com
coronavirus-2) [105]. Another report has suggested that the administration of heparin to
COVID-19 … in the development of heparin derivatives and conjugates as potential therapeutics. …

Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study

D Pereyra, S Heber, WC Schrottmaier… - Cardiovascular …, 2021 - academic.oup.com
… of hospitalized COVID-19 patients in Austria. We evaluated the predictive potential of previously
… Further, we explored the relationship between LMWH intake and potential underlying …

Low molecular weight heparin in adults inpatient COVID-19

JR Gonzalez-Porras, M Belhassen-Garcia… - 2020 - papers.ssrn.com
… prophylactic heparin in patients COVID-19. Based on their findings the usefulness of heparin
… But in addition, we suggest the intensity of thromboprophylaxis as potential factor related to …

[HTML][HTML] The potential role of therapeutic dose of low molecular weight heparin (LWMH) to attenuate hyper-inflammatory state in hospitalized COVID-19 patients

MS Mughal, IP Kaur, AR Jaffery, C Wang, M Asif… - Blood, 2020 - Elsevier
… This study involves a retrospective analysis of the potential role of an escalated dose of
LMWH to alter the hyper-inflammatory state in hospitalized patients with COVID-19 and …

[HTML][HTML] Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19

…, G Patti, COVID-UPO Clinical Team - Journal of thrombosis …, 2021 - Springer
… with COVID-19 for futility and potential harm [24]. Notably, in our study, the use of prophylactic
doses of enoxaparin in patients at low or intermediate baseline risk was associated with …

[HTML][HTML] Molecular mechanism of the anti-inflammatory action of heparin

L Litov, P Petkov, M Rangelov, N Ilieva… - International Journal of …, 2021 - mdpi.com
… , in particular with COVID-19. Our results put forward heparin as a promising means for the
Heparin as a potential inhibitor of viral attachment has been demonstrated for DENV [32]. In …